91 related articles for article (PubMed ID: 20101218)
1. NFAT3 transcription factor inhibits breast cancer cell motility by targeting the Lipocalin 2 gene.
Fougère M; Gaudineau B; Barbier J; Guaddachi F; Feugeas JP; Auboeuf D; Jauliac S
Oncogene; 2010 Apr; 29(15):2292-301. PubMed ID: 20101218
[TBL] [Abstract][Full Text] [Related]
2. Lipocalin 2, the TNF-like receptor TWEAKR and its ligand TWEAK act downstream of NFAT1 to regulate breast cancer cell invasion.
Gaudineau B; Fougère M; Guaddachi F; Lemoine F; de la Grange P; Jauliac S
J Cell Sci; 2012 Oct; 125(Pt 19):4475-86. PubMed ID: 22767506
[TBL] [Abstract][Full Text] [Related]
3. Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer.
Ding G; Fang J; Tong S; Qu L; Jiang H; Ding Q; Liu J
Prostate; 2015 Jun; 75(9):957-68. PubMed ID: 25728945
[TBL] [Abstract][Full Text] [Related]
4. Lipocalin 2 promotes the migration and invasion of esophageal squamous cell carcinoma cells through a novel positive feedback loop.
Du ZP; Wu BL; Xie YM; Zhang YL; Liao LD; Zhou F; Xie JJ; Zeng FM; Xu XE; Fang WK; Li EM; Xu LY
Biochim Biophys Acta; 2015 Oct; 1853(10 Pt A):2240-50. PubMed ID: 26190820
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of lipocalin-2 suppresses the growth and invasion of prostate cancer cells.
Tung MC; Hsieh SC; Yang SF; Cheng CW; Tsai RT; Wang SC; Huang MH; Hsieh YH
Prostate; 2013 Sep; 73(12):1281-90. PubMed ID: 23775308
[TBL] [Abstract][Full Text] [Related]
6. Thyroid hormone-mediated regulation of lipocalin 2 through the Met/FAK pathway in liver cancer.
Chung IH; Chen CY; Lin YH; Chi HC; Huang YH; Tai PJ; Liao CJ; Tsai CY; Lin SL; Wu MH; Chen CY; Lin KH
Oncotarget; 2015 Jun; 6(17):15050-64. PubMed ID: 25940797
[TBL] [Abstract][Full Text] [Related]
7. Lipocalin 2 promotes breast cancer progression.
Yang J; Bielenberg DR; Rodig SJ; Doiron R; Clifton MC; Kung AL; Strong RK; Zurakowski D; Moses MA
Proc Natl Acad Sci U S A; 2009 Mar; 106(10):3913-8. PubMed ID: 19237579
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor (ER)α-regulated lipocalin 2 expression in adipose tissue links obesity with breast cancer progression.
Drew BG; Hamidi H; Zhou Z; Villanueva CJ; Krum SA; Calkin AC; Parks BW; Ribas V; Kalajian NY; Phun J; Daraei P; Christofk HR; Hewitt SC; Korach KS; Tontonoz P; Lusis AJ; Slamon DJ; Hurvitz SA; Hevener AL
J Biol Chem; 2015 Feb; 290(9):5566-81. PubMed ID: 25468909
[TBL] [Abstract][Full Text] [Related]
9. HIC1 silencing in triple-negative breast cancer drives progression through misregulation of LCN2.
Cheng G; Sun X; Wang J; Xiao G; Wang X; Fan X; Zu L; Hao M; Qu Q; Mao Y; Xue Y; Wang J
Cancer Res; 2014 Feb; 74(3):862-72. PubMed ID: 24295734
[TBL] [Abstract][Full Text] [Related]
10. C/EBP ζ targets to neutrophil gelatinase-associated lipocalin (NGAL) as a repressor for metastasis of MDA-MB-231 cells.
Wang L; Li H; Wang J; Gao W; Lin Y; Jin W; Chang G; Wang R; Li Q; Ma L; Pang T
Biochim Biophys Acta; 2011 Oct; 1813(10):1803-13. PubMed ID: 21741997
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of aldo-keto reductase family 1 member C3 and its relationship with lipocalin 2 in cancer of the uterine cervix.
Wu CH; Ko JL; Chen SC; Lin YW; Han CP; Yang TY; Chien MH; Wang PH
Gynecol Oncol; 2014 Feb; 132(2):474-82. PubMed ID: 24316309
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis.
Leng X; Ding T; Lin H; Wang Y; Hu L; Hu J; Feig B; Zhang W; Pusztai L; Symmans WF; Wu Y; Arlinghaus RB
Cancer Res; 2009 Nov; 69(22):8579-84. PubMed ID: 19887608
[TBL] [Abstract][Full Text] [Related]
13. LCN2 Promoter Methylation Status as Novel Predictive Marker for Microvessel Density and Aggressive Tumor Phenotype in Breast Cancer Patients.
Meka Pb; Jarjapu S; Nanchari SR; Vishwakarma SK; Edathara PM; Gorre M; Cingeetham A; Vuree S; Annamaneni S; Dunna NR; Mukta S; B T; Satti V
Asian Pac J Cancer Prev; 2015; 16(12):4965-9. PubMed ID: 26163623
[TBL] [Abstract][Full Text] [Related]
14. ER stress drives Lipocalin 2 upregulation in prostate cancer cells in an NF-κB-dependent manner.
Mahadevan NR; Rodvold J; Almanza G; Pérez AF; Wheeler MC; Zanetti M
BMC Cancer; 2011 Jun; 11():229. PubMed ID: 21649922
[TBL] [Abstract][Full Text] [Related]
15. Lipocalin 2: a multifaceted modulator of human cancer.
Yang J; Moses MA
Cell Cycle; 2009 Aug; 8(15):2347-52. PubMed ID: 19571677
[TBL] [Abstract][Full Text] [Related]
16. Relationships of lipocalin 2 with breast tumorigenesis and metastasis.
Leng X; Wu Y; Arlinghaus RB
J Cell Physiol; 2011 Feb; 226(2):309-14. PubMed ID: 20857428
[TBL] [Abstract][Full Text] [Related]
17. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT.
Yoeli-Lerner M; Yiu GK; Rabinovitz I; Erhardt P; Jauliac S; Toker A
Mol Cell; 2005 Nov; 20(4):539-50. PubMed ID: 16307918
[TBL] [Abstract][Full Text] [Related]
18. Lipocalin 2 inhibits actin glutathionylation to promote invasion and migration.
Choudhary BS; Chaudhary N; Shah M; Dwivedi N; P K S; Das M; Dalal SN
FEBS Lett; 2023 Apr; 597(8):1086-1097. PubMed ID: 36650979
[TBL] [Abstract][Full Text] [Related]
19. Regulation of lipocalin-2 gene by the cancer chemopreventive retinoid 4-HPR.
Caramuta S; De Cecco L; Reid JF; Zannini L; Gariboldi M; Kjeldsen L; Pierotti MA; Delia D
Int J Cancer; 2006 Oct; 119(7):1599-606. PubMed ID: 16671099
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting metastatic breast cancer cell migration via the synergy of targeted, pH-triggered siRNA delivery and chemokine axis blockade.
Guo P; You JO; Yang J; Jia D; Moses MA; Auguste DT
Mol Pharm; 2014 Mar; 11(3):755-65. PubMed ID: 24467226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
